MUMBAI:
German company
, Merck announced it has entered into a collaboration and licensing agreement with
Domain Therapeutics
of France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
"This new generation of
adenosine receptor antagonists
are an important addition to our
immuno-oncology pipeline
,” said Laszlo Radvanyi senior VP- head of research in immuno-oncology at the biopharma business of Merck. “We plan to explore the promise of adenosine receptor antagonists and develop novel compounds to potentially use in new combination immunotherapies for cancer.”
Adenosine receptor antagonists are small molecules thought to slow tumor progression and improve the response to combination immunotherapies by Inhibiting adenosine– a compound generated by cancer cells that inhibits anti-tumor responses by binding to T cells, says a company statement.
The agreement will involve a close collaboration between Merck and Domain Therapeutics to develop and test new agents targeting key adenosine receptors. Merck will support research activities and gain worldwide rights to Domain’s next generation of adenosine receptor inhibitors.
Stay informed with the latest Business News on Times of India. Explore updates on International Business, gain insights with Financial Literacy tips, and make use of Financial Calculators. Don’t forget to check the list of Bank Holidays in 2025, including Bank Holidays in January.
A business journalist with around two decades of experience track...
Read MoreA business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government. Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.
Read Less